Answers are grounded in this paper and cite their sources.
were more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination treatment with docetaxel. In conclusion, our study supports the use of DEAB as an ALDH inhibitor but also reveals closely related analogues with increased selectivity and potency.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: